Pfizer Kickback Ruling Shows Drug Copay Program Risks
In a recent decision, the U.S. Court of Appeals for the Second Circuit upheld the U.S. Department of Health and Human Services Office of the Inspector General's position that Pfizer Inc.'s...To view the full article, register now.
Already a subscriber? Click here to view full article